New and emerging treatments for Parkinson disease

Victor S C Fung
Med J Aust 2015; 202 (6): 283-284. || doi: 10.5694/mja15.00155

The main aim is to maintain quality of life throughout the illness

World Parkinson's Day commemorates the birth of James Parkinson on 11 April 1755, and it will soon be the 200th anniversary of his description of the “shaking palsy”.1 In this article I highlight some of the advances in Parkinson disease (PD) therapy since the topic was most recently reviewed in the Journal.2

Please login with your free MJA account to view this article in full

  • Victor S C Fung1,2

  • 1 Westmead Hospital, Sydney, NSW.
  • 2 University of Sydney, Sydney, NSW.


Competing interests:

I have been on advisory boards for Abbott, AbbVie, Allergan, Boehringer-Ingelheim, Hospira, Ipsen, Lundbeck, Novartis, Global Kinetics Corporation, Solvay and UCB, and serve on the editorial boards of Movement Disorders, NPJ Parkinson's Disease, Movement Disorders Clinical Practice, Journal of Clinical Movement Disorders, F1000Research and Basal Ganglia.

  • 1. Parkinson J. An essay on the shaking palsy. 1st ed. London: Wittington and Newland, 1817.
  • 2. Hayes MW, Fung VS, Kimber TE, O'Sullivan JD. Current concepts in the management of Parkinson disease. Med J Aust 2010; 192: 144-149. <MJA full text>
  • 3. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17: 60-67.
  • 4. Williams DR, Lees AJ. How do patients with parkinsonism present? A clinicopathological study. Intern Med J 2009; 39: 7-12.
  • 5. European Parkinson's Disease Association. EPDA charter, 1997. (accessed Mar 2015).
  • 6. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399-406.
  • 7. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20: 5-15.
  • 8. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
  • 9. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311: 1670-1683.
  • 10. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284: 1931-1938.
  • 11. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589-595.
  • 12. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
  • 13. PD Med Collaborative Group, Gray R, Ives N, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014; 384: 1196-1205.
  • 14. Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson's disease. Mov Disord 2014; 29: 23-32.
  • 15. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896-908.
  • 16. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301: 63-73.
  • 17. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010; 9: 581-591.
  • 18. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13: 141-149.
  • 19. Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord 2014; 24 Dec [Epub ahead of print].
  • 20. Antonini A, Yegin A, Preda C, et al. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 2015; 21: 231-235.
  • 21. Klingelhoefer L, Samuel M, Chaudhuri KR, Ashkan K. An update of the impact of deep brain stimulation on non motor symptoms in Parkinson's disease. J Parkinsons Dis 2014; 4: 289-300.
  • 22. Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord 2014; 10 Nov [Epub ahead of print].
  • 23. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 96-101.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.